VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
May 04 2021 - 8:00AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression, and other central nervous system (“CNS”)
disorders, today announced the appointment of Ann Cunningham as its
Chief Commercial Officer. Ms. Cunningham has a proven
pharmaceutical commercial track record of more than 25 years
delivering sales, marketing, and global life cycle product
management expertise in roles across several healthcare markets,
including neuropsychiatry and other CNS markets that VistaGen is
pursuing. She has been serving on VistaGen’s Board of Directors
(“Board”) since January 2019 and will remain a member of the Board.
“Since joining our Board, Ann’s commercial
insight, expertise and leadership experience has been tremendously
helpful in support of our pre-commercial planning for PH94B, with
special emphasis on a broad range of anxiety markets in the U.S.
With the near term launch of our Phase 3 clinical development
program for PH94B, our investigational product focused on the acute
treatment of anxiety in adults with social anxiety disorder, Ann’s
appointment as our Chief Commercial Officer adds considerable
strength to the world-class team we have assembled across all key
functional areas necessary to advance our company through the next
phases of our growth,” said Shawn Singh, Chief Executive Officer of
VistaGen. “Ann’s many notable accomplishments throughout her
distinguished career in the pharmaceutical industry include leading
campaigns for prominent neuropsychiatric drug treatments in
multiple markets where we believe our investigational products,
including PH94B, have therapeutic and commercial potential. As we
look to transition from clinical development into a commercial
growth mode and steadfastly pursue our mission to create
life-changing medicines to improve mental health and well-being,
Ann’s leadership will make a difference.”
“Serving on the VistaGen Board has allowed me to
gain important insight into the ongoing development of VistaGen’s
potentially life-changing CNS product candidates. I am thrilled to
expand my role, join the team full time, and lead the company’s
commercial efforts. The company’s innovative fast-acting, new
generation CNS drug candidates have exciting potential in large
markets where millions of individuals need novel products that are
safe and effective alternatives to current treatments,” said
Cunningham. “As VistaGen progresses its late-stage product
candidates, I am excited to ensure that the company will be well
prepared and strategically positioned to build brand awareness for
our lead product candidate, PH94B, and to accelerate its adoption,
as well as that of our other pipeline products, once approved,
across these large target markets.”
Most recently, Ms. Cunningham served as Managing
Partner of i3 Strategy Partners, where she guided
pharmaceutical and biotechnology executives in planning and
executing successful portfolio strategies and brand launches by
evaluating key business questions and unique strategies to unlock
the full potential of each organization served. Her experience in
the pharmaceutical industry includes multiple instrumental roles,
including Vice President, Neurodegenerative Disease and Psychiatry
at Teva Pharmaceutical Industries; Senior Director, Global Brand
Lead, Rexulti, at Otsuka America Pharmaceutical; and Senior
Director, Global Brand Lead and Sales Director in multiple
therapeutic areas, including Psychiatry, at Eli Lilly and Company.
Ms. Cunningham holds a B.A. in Psychology from Yale University and
an M.B.A. from the University of Michigan, Stephen M. Ross School
of Business.
About VistaGenVistaGen
Therapeutics is a biopharmaceutical company committed to developing
and commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three drug candidates has a
differentiated potential mechanism of action, has been
well-tolerated in all clinical studies to date, and has therapeutic
potential in multiple CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on Twitter,
LinkedIn, and Facebook.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as “may,” “could,” “expect,” “project,” “outlook,”
“strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “strive,” “goal,” “continue,”
“likely,” “will,” “would” and variations of these terms and similar
expressions, or the negative of these terms or similar expressions.
Such forward-looking statements are necessarily based upon
estimates and assumptions that, while considered reasonable by us
and our management, are inherently uncertain. Our actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
relating to delays in launching and/or conducting our planned
clinical trials, including delays due to the impact of the COVID-19
pandemic; fluctuating costs of materials and other resources
required to conduct our planned clinical and non-clinical trials;
continued uncertainty with respect to the COVID-19 pandemic; market
conditions; the impact of general economic, industry or political
conditions in the United States or internationally; adverse
healthcare reforms and changes of laws and regulations;
manufacturing and marketing risks, including risks related to the
COVID-19 pandemic, which may include, but are not limited to,
unavailability of or delays in delivery of raw materials for
manufacture of our CNS drug candidates and difficulty in initiating
or conducting clinical trials; inadequate and/or untimely supply of
one or more of our CNS drug candidates to meet demand; entry of
competitive products; and other technical and unexpected hurdles in
the development, manufacture and commercialization of our CNS drug
candidates; and the risks more fully discussed in the section
entitled "Risk Factors" in our most recent Annual Report on Form
10-K for the year ended March 31, 2020, and in our most recent
Quarterly Report on Form 10-Q for the quarter ended December 31,
2020, as well as discussions of potential risks, uncertainties, and
other important factors in our other filings with the U.S.
Securities and Exchange Commission (SEC). Our SEC filings are
available on the SEC’s website at www.sec.gov. You should not place
undue reliance on these forward-looking statements, which apply
only as of the date of this press release and should not be relied
upon as representing our views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements, other than as may be required by law. If we do update
one or more forward-looking statements, no inference should be made
that we will make additional updates with respect to those or other
forward-looking statements.
VistaGen Company ContactsMark McPartland / Mark
FlatherVistaGen Therapeutics Phone: (650) 577-3606Email:
IR@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Sep 2023 to Sep 2024